Thumbs-up on BMS-Celgene deal ends months of activist outrage by Arlene Weintraub Friday, April 12, 2019 With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.
How and Why Celgene Adopted Medidata Rave eCOA Sponsored by Medidata Thursday, May 16, 2019 If your company is looking to adopt a new eCOA solution or have issues with your current one, this webinar is a must attend.
Starboard ends BMS proxy war after advisories back Celgene deal by Carly Helfand Monday, April 1, 2019 Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.
Proxy adviser backing boost odds for BMS-Celgene merger by Carly Helfand Friday, March 29, 2019 When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up.
FTC zeroes in on potential BMS, Celgene psoriasis overlap by Carly Helfand Tuesday, March 26, 2019 Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.
Could proxy advisers sway votes against BMS-Celgene merger? by Arlene Weintraub Thursday, March 21, 2019 Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.
Without 'smoking gun,' BMS, Celgene deal will close: analyst by Eric Sagonowsky Tuesday, March 19, 2019 Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go through.
Bristol's Celgene quest gets a boost from Revlimid patent win by Carly Helfand Thursday, March 14, 2019 Much of the doubt surrounding BMS' $74 billion Celgene buy centers on Revlimid's patent life. But the companies just scored a win in that department.
Could a Celgene patent dispute tank the BMS deal? by Arlene Weintraub Wednesday, March 13, 2019 Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
